Evofem Biosciences, Inc.EVFMOTCMARKET
Loading
SG&A Expense Growth Recovery in ProgressRecovering
Percentile Rank47
5Y CAGR-53.4%
Year-over-Year Change
Year-over-year SG&A expense growth
5Y CAGR
-53.4%/yr
Long-term compound
Percentile
P47
Within normal range
vs 5Y Ago
0x
Contraction
Streak
2 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q3 2025 | 0.25% |
| Q2 2025 | -10.03% |
| Q1 2025 | -11.76% |
| Q4 2024 | 3.57% |
| Q3 2024 | 20.49% |
| Q2 2024 | -12.75% |
| Q1 2024 | -12.12% |
| Q4 2023 | -3.73% |
| Q3 2023 | -4.46% |
| Q2 2023 | -8.22% |
| Q1 2023 | -23.11% |
| Q4 2022 | -50.23% |
| Q3 2022 | -15.01% |
| Q2 2022 | 1.71% |
| Q1 2022 | -31.11% |
| Q4 2021 | -13.69% |
| Q3 2021 | 5.27% |
| Q2 2021 | -10.70% |
| Q1 2021 | 27.90% |
| Q4 2020 | 36.00% |
| Q3 2020 | 11.22% |
| Q2 2020 | 31.93% |
| Q1 2020 | 60.13% |
| Q4 2019 | 7.61% |
| Q3 2019 | 29.25% |
| Q2 2019 | 16.77% |
| Q1 2019 | 10.38% |
| Q4 2018 | -39.61% |
| Q3 2018 | -24.92% |
| Q2 2018 | 26.58% |
| Q1 2018 | 348.61% |
| Q4 2017 | 50.67% |
| Q3 2017 | 4.82% |
| Q2 2017 | -13.63% |
| Q1 2017 | 40.69% |
| Q4 2016 | 17.39% |
| Q3 2016 | 0.00% |